<?xml version="1.0" encoding="UTF-8"?>
<ref id="B124-nanomaterials-10-01072">
 <label>124.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Liu</surname>
    <given-names>Y.V.</given-names>
   </name>
   <name>
    <surname>Massare</surname>
    <given-names>M.J.</given-names>
   </name>
   <name>
    <surname>Barnard</surname>
    <given-names>D.L.</given-names>
   </name>
   <name>
    <surname>Kort</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Nathan</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Smith</surname>
    <given-names>G.</given-names>
   </name>
  </person-group>
  <article-title>Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV</article-title>
  <source>Vaccine</source>
  <year>2011</year>
  <volume>29</volume>
  <fpage>6606</fpage>
  <lpage>6613</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.111</pub-id>
  <pub-id pub-id-type="pmid">21762752</pub-id>
 </element-citation>
</ref>
